A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
Vorinostat has been studied across 18 research domains including 🔬 Oncology, 🛡️ Immunity, ⏳ Longevity & Aging, ✨ Skin & Hair, 🔬 Inflammation. The primary research focus is 🔬 Oncology with 68% of studies addressing this area.
The following compounds share molecular targets with Vorinostat, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Vorinostat is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.